2.315
Humacyte Inc stock is traded at $2.315, with a volume of 2.91M.
It is up +10.77% in the last 24 hours and down -13.30% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$2.09
Open:
$2.11
24h Volume:
2.91M
Relative Volume:
0.61
Market Cap:
$414.17M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-2.1636
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
+3.81%
1M Performance:
-13.30%
6M Performance:
-54.16%
1Y Performance:
-56.89%
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
HUMA
Humacyte Inc
|
2.315 | 414.17M | 0 | -110.78M | -75.59M | -1.07 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
452.96 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
539.18 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.24 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
551.27 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.57 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-14-25 | Resumed | H.C. Wainwright | Buy |
Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
Dec-11-23 | Initiated | H.C. Wainwright | Buy |
Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
Oct-29-21 | Initiated | Cowen | Outperform |
Sep-24-21 | Initiated | Oppenheimer | Outperform |
Sep-22-21 | Initiated | BTIG Research | Buy |
Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know - Yahoo Finance
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. LawsuitHUMA - ACCESS Newswire
Humacyte: Revenue Ramp From Symvess Incoming (NASDAQ:HUMA) - Seeking Alpha
Humacyte (HUMA) Maintains "Buy" Rating with $25 Price Target | H - GuruFocus
Humacyte (HUMA) Phase 3 Trial Highlights Advantages of Engineered Vessel for Hemodialysis | HUMA Stock News - GuruFocus
Humacyte, Inc. Announces the Results from Its V007 Pivotal Phase 3 Clinical Trial of the Acellular Tissue Engineered Vessel - MarketScreener
Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting - The Manila Times
Phase 3 Trial: Humacyte Vessel Outperforms Standard Dialysis Access in High-Risk Patients | HUMA Stock News - Stock Titan
Humacyte Paradoxically Scales Back As Symvess Begins Its Long Journey (NASDAQ:HUMA) - Seeking Alpha
Humacyte, Inc. (NASDAQ:HUMA) Short Interest Up 20.7% in May - Defense World
Nuveen Asset Management LLC Lowers Stake in Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Shareholders - ACCESS Newswire
Cetera Investment Advisers Buys 9,134 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Humacyte (HUMA) to Present Phase 3 Trial Results at Vascular Sur - GuruFocus
Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3 - TradingView
Breakthrough: Humacyte's Bioengineered Vessel Outperforms Standard Treatment in Phase 3 Dialysis Trial - Stock Titan
Humacyte, Inc. (NASDAQ:HUMA) Shares Acquired by ProShare Advisors LLC - Defense World
BNP Paribas Financial Markets Buys Shares of 14,613 Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Humacyte, Inc. (NASDAQ:HUMA) Shares Bought by Bank of America Corp DE - Defense World
Deutsche Bank AG Purchases 26,419 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic? - Nasdaq
Humacyte, Inc. (NASDAQ:HUMA) Q1 2025 Earnings Call Transcript - MSN
Millennium Management LLC Sells 348,653 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World
$HUMA - Binance
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet - MSN
Northern Trust Corp Purchases 92,708 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Is Humacyte (NASDAQ:HUMA) A Risky Investment? - simplywall.st
Humacyte, Inc. (NASDAQ:HUMA) Receives $11.71 Average PT from Brokerages - Defense World
Humacyte at H.C. Wainwright Conference: Promising Developments in SimVess By Investing.com - Investing.com Nigeria
Humacyte at H.C. Wainwright Conference: Promising Developments in SimVess - Investing.com Australia
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq - The Manila Times
Humacyte CEO Reveals Latest Bioengineered Tissue Developments at Elite Nasdaq Conference - Stock Titan
Price T Rowe Associates Inc. MD Has $172,000 Stock Holdings in Humacyte, Inc. (NASDAQ:HUMA) - Defense World
What is HC Wainwright’s Estimate for Humacyte Q2 Earnings? - Defense World
Humacyte’s Earnings Call Highlights Success and Challenges - TipRanks
Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates - MSN
Humacyte (HUMA) Receives Buy Rating and $4.00 Price Target from HC Wainwright & Co. | HUMA Stock News - GuruFocus
Humacyte (HUMA) Gains Buy Rating with $4 Target | HUMA Stock New - GuruFocus
Benchmark cuts Humacyte stock target to $14, maintains Buy rating By Investing.com - Investing.com South Africa
Humacyte (HUMA) Reports Lower-Than-Expected Q1 Revenue Amid Symv - GuruFocus
Humacyte, Inc.: Spare Parts for People - Outsider Club
Humacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026 - MSN
Humacyte (HUMA) Gains Buy Rating with $4 Target | HUMA Stock News - GuruFocus
Benchmark cuts Humacyte stock target to $14, maintains Buy rating - Investing.com
Humacyte (HUMA) Price Target Reduced by Benchmark Amid Positive Outlook | HUMA Stock News - GuruFocus
Humacyte (HUMA) Focuses on Symvess Launch and Expansion Plans - GuruFocus
Humacyte price target lowered to $14 from $17 at Benchmark - TipRanks
Durham firm with battered stock cuts jobs to save cash - The Business Journals
Humacyte Reports Q1 2025 Earnings and Strategic Progress - TipRanks
Earnings call transcript: Humacyte Q1 2025 beats EPS forecast, stock surges - Investing.com Nigeria
Humacyte, Inc. SEC 10-Q Report - TradingView
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Humacyte Inc Stock (HUMA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Sander Dale A. | CFO and Chief Corp. Deve. Off. |
Apr 10 '25 |
Buy |
1.53 |
20,000 |
30,600 |
40,600 |
Parikh Shamik J | Chief Medical Officer |
Apr 10 '25 |
Buy |
1.55 |
7,500 |
11,625 |
7,500 |
Sebelius Kathleen | Director |
Apr 08 '25 |
Buy |
1.32 |
50,000 |
66,000 |
91,207 |
Green Charles Bruce | Director |
Apr 08 '25 |
Buy |
1.29 |
6,000 |
7,740 |
8,400 |
Constantino Michael T. | Director |
Apr 07 '25 |
Buy |
1.26 |
16,000 |
20,160 |
32,950 |
Constantino Michael T. | Director |
Dec 04 '24 |
Buy |
4.39 |
4,600 |
20,181 |
16,950 |
Niklason Laura E | President, CEO and Director |
Nov 19 '24 |
Buy |
4.44 |
1,797 |
7,979 |
243,851 |
Dougan Brady W | Director |
Nov 19 '24 |
Buy |
4.44 |
1,797 |
7,979 |
243,851 |
Niklason Laura E | President, CEO and Director |
Nov 18 '24 |
Sale |
4.44 |
811,172 |
3,601,604 |
2,419,712 |
Niklason Laura E | President, CEO and Director |
Nov 19 '24 |
Sale |
4.34 |
427,459 |
1,855,172 |
1,992,253 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):